The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy. (1st January 2019)

• Record Type: Journal Article
• Authors: Guo, Ning; Liu, Shengli; Bow, Laurine M; Cui, Xianquan; Zhang, Luwei; Xu, Shihao; Lu, Sai; Tian, Jun
• Is Part Of: Renal failure. Volume 41:Number 1(2019)
• Page Start: 334
• Page End: 339
• Publication Date: 2019-01-01
• Subjects: IgA nephropathy -- rapamycin -- animal model -- mTOR pathway; Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.1080/0886022X.2019.1577257
• Languages: English
• ISSNs: 0886-022X

Abstract

Abstract: Background: The pathogenesis of the development of IgA nephropathy has not been clear up to now. At present, some studies revealed that the mTOR pathway may participate in IgA nephropathy; however, the mechanism has not been systematically studied. In this study, we established an IgAN rat model to investigate the protective effects of rapamycin as a new type of immunosuppressant, as well as its therapeutic mechanisms. Methods: After the establishment of IgA nephropathy model, rats were treated with different concentrations of rapamycin, and the protective effect of different concentrations of rapamycin on renal function of the rats was observed. The deposition of IgA was observed by immunofluorescence. The kidney expression of Akt and p70S6k proteins in mTOR pathway was examined using the western blot assay after rapamycin treatment. Results: Morphology and immunofluorescence confirmed that the rat model of IgA nephropathy was successfully established. In particular, the level of proteinuria decreased with the increase of the dose of rapamycin, as well as the deposition of IgA in glomeruli. Moreover, the western blot analysis indicated that the expression of p70S6K in the downstream of mTOR pathway decreased and the upstream protein AKT of the mTOR pathway was overexpressed in the rats model. Conclusion: We found that rapamycin has protective effects in the IgA nephropathy rat model in a dose-dependent manner. In addition, the result of western blot assay suggested that rapamycin may display its therapeutic effects through interfering the AKT-mTOR-p70S6K signaling pathway.